Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Trastuzumab is commonly utilized in the management of metastatic HER2-positive breast cancer. Our main goal was to examine the clinical outcomes and immune markers of patients who received trastuzumab and chemotherapy treatment. Methods: Between 1995 and 2012, a total of 98 patients diagnosed with metastatic HER2-positive breast cancer were retrospectively analyzed at Ege University Hospital and Tepecik Training and Research Hospital. The clinicopathological characteristics and clinical outcomes of the patients were assessed, and the associations between response rates, survival and the immune profiles of tumor infiltrating lymphocytes were statistically evaluated. Results: The average age of patients at the time of diagnosis was 50.1±10.3 (ranging from 30 to 79) years. The mean follow-up period for all patients was 97.9±53.8 months. Among the patients, complete response was observed in 24.5%, partial response in 61.2%, and stable disease in 8.2% of cases. The average progression-free survival was 50.3±26.9 months (ranging from 1 to 163 months), and the average overall survival was 88.8±59.4 months (ranging from 12 to 272 months). After analyzing all cases, it was found that patients who were younger (p=0.006), exhibited higher CD3-positivity (p=0.041), presented with higher FOXP3-positivity (p=0.025), showed complete or at least partial response to treatment (p=0.008), and experienced a long-term response to trastuzumab (and chemotherapy) treatment had longer survival (p=0.001). Conclusion: Patients with HER2-positive breast cancer, who initially respond positively to palliative trastuzumab and chemotherapy treatment, can achieve long-term tumor remission lasting for several years.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study
- Date Crossref
- 01/09/2024
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Izmir University pays non établi dans la noticeUniversité ou école supérieure
-
Sağlık Bilimleri Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
İzmir Demokrasi Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Manisa Celal Bayar University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Çanakkale Onsekiz Mart Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Health Sciences University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Izmir Democracy University Department of Pathology pays non établi dans la noticeUniversité ou école supérieure
-
University of Health Sciences Department of Pathology pays non établi dans la noticeUniversité ou école supérieure
-
Canakkale Onsekiz Mart University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
izmir Medicana Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
Izmir University, Sağlık Bilimleri Üniversitesi et İzmir Demokrasi Üniversitesi, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.